Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.
The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
A Colton-supported NYU Langone study has engineered a bispecific antibody that precisely silences harmful T cell activity — showing promise across mouse models of type 1 diabetes, hepatitis, and multiple sclerosis.
The 2025 Penn Colton Center Symposium convened 150+ experts to explore breakthroughs in immune health and spotlight Penn's leadership, future headquarters, and innovations in autoimmunity research and precision medicine.
A Colton-supported NYU study published in Science Immunology has discovered that the immune checkpoint protein PD-1 functions as a dimer — a finding that could transform drug design for both cancer and autoimmune disease.
Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.
Yale's Colton Center for Autoimmunity has awarded $750,000 to seven faculty-led projects advancing research into autoimmune and allergic diseases, with funding, mentorship, and commercialization support.
Penn Medicine's new Colton Center for Autoimmunity unites the university's immunology research and patient care programs, joining NYU and Yale in a shared effort to advance autoimmune disease diagnosis and treatment.
Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
